Moderna is attempting to “coopt an entire field of mRNA technology,” the companies said in two petitions seeking inter partes review filed at the patent office’s administrative tribunal on Monday. US Patent Nos. 10,933,127 and 10,702,600 should be canceled because they are anticipated and obvious in light of prior art, they argued.
The two challenged patents have “unimaginably broad claims” relating to mRNA composition and administration of an mRNA vaccine, according …
